BioSpace News Archive

Business

Tessera Therapeutics Appoints Industry Leaders Elliott Sigal & Mary Rozenman to Board of Directors

Tessera Therapeutics announced today the appointment of Elliott Sigal, M.D., Ph.D. and Mary Rozenman, Ph.D. to the company’s Board of Directors.

June 15, 2021
·
5 min read
Preclinical Data from ImmunoPrecise’s Drug Pipeline to be Presented During the BIO International Partnering Event

IMMUNOPRECISE ANTIBODIES LTD will be presented in partnering meetings at the 2021 BIO International Convention, June 14-18, 2021.

June 15, 2021
·
6 min read
Viewpoint Molecular Targeting(TM) Discusses the Promise of Image-Guided 212Pb Alpha-Particle Radiopharmaceutical Therapies for Cancer at the SNMMI 2021 Annual Meeting

Viewpoint Molecular Targeting, Inc. today announced that Michael K. Schultz PhD, Chief Science Officer of Viewpoint presented at The Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, held virtually June 11-15, 2021.

June 15, 2021
·
3 min read
Business

ENDRA Life Sciences Appoints Irina Pestrikova as Senior Director of Finance, Announces Departure of CFO David Wells

ENDRA Life Sciences Inc., a pioneer of Thermo Acoustic Enhanced UltraSound, announced the appointment of Irina Pestrikova as Senior Director of Finance and Principal Financial Officer.

June 15, 2021
·
4 min read
Business

Polydex Pharmaceuticals Issues First Quarter Financial ResultsPrudent Cash Management Sustains Company Through Adverse Conditions

Polydex Pharmaceuticals Limited reports financial results for the first quarter of fiscal 2022, the period ended April 30, 2021.

June 15, 2021
·
2 min read
Pharm Country

Safety Data Highlighting Low Rates of Adverse Events and Non-Relapse Transplant Related Mortality in Patients Receiving Iomab-B Presented at 2021 SNMMI Virtual Conference

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium”) today highlighted safety data from its ongoing pivotal Phase 3 SIERRA trial of Iomab-B in patients with relapsed or refractory Acute Myeloid Leukemia (r/r AML) were presented at the 2021 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held virtually July 11th – 14th.

June 15, 2021
·
8 min read
Pharm Country

The Michael J. Fox Foundation Releases New Guide, Deep Brain Stimulation and Parkinson’s

With an estimated 6 million people worldwide living with Parkinson’s, and an estimated 60,000 newly diagnosed annually, resources to help navigate available treatments to manage Parkinson’s care are critical.

June 15, 2021
·
6 min read
Recursion Announces its First Major Multidisciplinary Expansion, in Toronto, to Further Tech-Enabled Drug Discovery

Recursion announced its intention to soon launch its first major multidisciplinary expansion beyond its Utah headquarters, with plans to hire up to 50 people in Toronto by the end of 2021.

June 15, 2021
·
6 min read
Genetown

NeuroMetrix Reports that Quell® Technology is to be Evaluated for Neuromyelitis Optica Spectrum Disorder (NMOSD) in a Randomized Controlled Trial

NeuroMetrix, Inc. (Nasdaq: NURO) today announced that Quell technology will be used in a double-blinded, randomized, sham-controlled trial to determine whether transcutaneous electrical nerve stimulation (TENS) is an effective, acceptable and feasible method of pain relief in patients with NMOSD.

June 15, 2021
·
2 min read
Drug Development

Optimi Health Completes Pre-Clinical Trial Application MeetingCompany Advised by Health Canada to Proceed with Phase 1 Psilocybin Study Application

Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), partners with Numinus Wellness Inc. have been advised by their clinical trials administrators that they have received Health Canada approval to proceed with a formal submission to initiate their previously proposed phase 1 study.

June 15, 2021
·
6 min read